123 related articles for article (PubMed ID: 17345072)
1. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
[TBL] [Abstract][Full Text] [Related]
3. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting drug concentrations and QT interval during thioridazine therapy.
Thanacoody RH; Daly AK; Reilly JG; Ferrier IN; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):555-65. PubMed ID: 17460606
[TBL] [Abstract][Full Text] [Related]
6. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
[TBL] [Abstract][Full Text] [Related]
7. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
Salih IS; Thanacoody RH; McKay GA; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
[TBL] [Abstract][Full Text] [Related]
10. Absorption and excretion of thioridazine and mesoridazine in man.
Charalampous KD; Johnson PC; Estevez V
Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
[TBL] [Abstract][Full Text] [Related]
11. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
12. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
Niedzwiecki DM; Mailman RB; Cubeddu LX
J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
[TBL] [Abstract][Full Text] [Related]
13. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926
[TBL] [Abstract][Full Text] [Related]
15. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
Rao ML; Brown WA; Wagner R
Ther Drug Monit; 1988; 10(2):184-7. PubMed ID: 3381236
[TBL] [Abstract][Full Text] [Related]
16. Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs.
Lin G; Chu KW; Damani LA; Hawes EM; Midha KK
J Pharm Biomed Anal; 1996 Apr; 14(6):727-38. PubMed ID: 8807548
[TBL] [Abstract][Full Text] [Related]
17. Identification of a metabolite of thioridazine and mesoridazine from human plasma.
Gruenke LD; Craig JC
Res Commun Chem Pathol Pharmacol; 1975 Feb; 10(2):221-5. PubMed ID: 1162173
[TBL] [Abstract][Full Text] [Related]
18. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
Eap CB; Souche A; Koeb L; Baumann P
Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
[TBL] [Abstract][Full Text] [Related]
19. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
LLerena A; Berecz R; de la Rubia A; Dorado P
J Psychopharmacol; 2002 Dec; 16(4):361-4. PubMed ID: 12503836
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.
Eap CB; Guentert TW; Schãublin-Loidl M; Stabl M; Koeb L; Powell K; Baumann P
Clin Pharmacol Ther; 1996 Mar; 59(3):322-31. PubMed ID: 8653995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]